v3.25.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock
2023 Neurocrine Collaborative Agreement
Common Stock
2023 Novartis Collaboration Agreement
Common Stock
Additional Paid-In Capital
2023 Neurocrine Collaborative Agreement
Additional Paid-In Capital
2023 Novartis Collaboration Agreement
Additional Paid-In Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
2023 Neurocrine Collaborative Agreement
2023 Novartis Collaboration Agreement
Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2022     $ 38     $ 452,713 $ (219) $ (393,512)     $ 59,020
Shares, Outstanding, Beginning Balance at Dec. 31, 2022     38,613,891                
Exercises of vested stock options     $ 1     1,851         1,852
Exercises of vested stock options (in shares)     385,655                
Vesting of restricted stock units (in shares)     531,560                
Issuance of common stock in connection with agreement $ 5     $ 31,116         $ 31,121    
Issuance of common stock in connection with agreement (in shares) 4,395,588                    
Issuance of common stock under ESPP           959         959
Issuance of common stock under ESPP (in shares)     111,639                
Stock-based compensation expense           10,867         10,867
Unrealized gain (loss) on available-for-sale securities, net of tax             171       171
Net (loss) income               132,330     132,330
Stockholders' Equity, Ending Balance at Dec. 31, 2023     $ 44     497,506 (48) (261,182)     236,320
Shares, Outstanding, Ending Balance at Dec. 31, 2023     44,038,333                
Exercises of vested stock options           388         388
Exercises of vested stock options (in shares)     106,831                
Vesting of restricted stock units     $ 1               1
Vesting of restricted stock units (in shares)     515,303                
Issuance of common stock in connection with agreement   $ 2     $ 19,303         $ 19,305  
Issuance of common stock in connection with agreement (in shares)   2,145,002                  
Issuance of common stock and pre-funded warrants in connection with underwritten public offering     $ 8     93,465         93,473
Issuance of common stock and pre-funded warrants in connection with underwritten public offering (in shares )     7,777,778                
Issuance of common stock under ESPP           1,172         1,172
Issuance of common stock under ESPP (in shares)     148,069                
Stock-based compensation expense           14,462         14,462
Unrealized gain (loss) on available-for-sale securities, net of tax             (359)       (359)
Net (loss) income               (65,002)     (65,002)
Stockholders' Equity, Ending Balance at Dec. 31, 2024     $ 55     626,296 (407) (326,184)     299,760
Shares, Outstanding, Ending Balance at Dec. 31, 2024     54,731,316                
Exercises of vested stock options     $ 1     266         $ 267
Exercises of vested stock options (in shares)     91,489               91,489
Vesting of restricted stock units (in shares)     691,107                
Issuance of common stock from the exercise of pre-funded warrants     $ 3     (3)          
Issuance of common stock from the exercise of pre-funded warrants (in shares)     3,332,544                
Issuance of common stock under ESPP           549         $ 549
Issuance of common stock under ESPP (in shares)     201,404                
Stock-based compensation expense           14,787         14,787
Unrealized gain (loss) on available-for-sale securities, net of tax             439       439
Net (loss) income               (119,721)     (119,721)
Stockholders' Equity, Ending Balance at Dec. 31, 2025     $ 59     $ 641,895 $ 32 $ (445,905)     $ 196,081
Shares, Outstanding, Ending Balance at Dec. 31, 2025     59,047,860